Infosys Public Services, Inc., a US based subsidiary of Infosys, today announced that it has been selected byPrime Therapeutics LLC (Prime Therapeutics), a leading pharmacy benefit manager (PBM), to set up a testing center of excellence (COE) and consolidate the delivery of its application testing services as part of a new three-year contract.
Prime Therapeutics will streamline and optimize its quality assurance (QA) and testing services as well as enhance its competitiveness with Infosys Public Services’ expertise and world-class delivery model. Prime Therapeutics also expects to expand the capabilities of its QA organization and gain efficiencies in managing a large scale QA department.
We look forward to bringing our deep experience in the health care industry and pharmacy benefit management in particular as well as globally benchmarked QA and testing service delivery to Prime Therapeutics,” said Eric Paternoster, President & CEO, Infosys Public Services, Inc. “This agreement will allow us to help the company sharpen its focus on providing better care and services to their members.”
- Prime Therapeutics selected Infosys Public Services for its health care and pharmacy benefit management expertise, proven experience with QA and testing COEs, and service delivery capabilities.
- As part of the contract, Infosys Public Services will consolidate and standardize Prime Therapeutics’ QA and testing services, currently provided by multiple service providers.
- Infosys Public Services will support Prime Therapeutics’ QA organization as they deliver across all lines of the business and increase the agility of the QA department.
- Prime Therapeutics will be able to improve application and service quality, and reduce IT costs with Infosys Public Services’ range of QA and testing frameworks, techniques, tools and accelerators.
“The rapidly evolving health care industry demands faster response and improved information technology quality to ensure Prime Therapeutics’ competitiveness,” said Jim Graham, Vice President Application Development, Prime Therapeutics. “Transforming our testing and QA services will help us achieve that and better meet the needs of health plans, employers, and government programs.”